全文获取类型
收费全文 | 444篇 |
免费 | 33篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 12篇 |
基础医学 | 44篇 |
口腔科学 | 8篇 |
临床医学 | 30篇 |
内科学 | 67篇 |
皮肤病学 | 2篇 |
神经病学 | 5篇 |
特种医学 | 243篇 |
外科学 | 17篇 |
综合类 | 8篇 |
预防医学 | 8篇 |
眼科学 | 3篇 |
药学 | 14篇 |
肿瘤学 | 20篇 |
出版年
2021年 | 3篇 |
2020年 | 3篇 |
2019年 | 7篇 |
2018年 | 4篇 |
2017年 | 2篇 |
2015年 | 2篇 |
2012年 | 7篇 |
2011年 | 4篇 |
2010年 | 6篇 |
2009年 | 8篇 |
2008年 | 6篇 |
2007年 | 13篇 |
2006年 | 8篇 |
2005年 | 2篇 |
2004年 | 4篇 |
2003年 | 6篇 |
2002年 | 3篇 |
2001年 | 6篇 |
2000年 | 2篇 |
1999年 | 2篇 |
1998年 | 20篇 |
1997年 | 23篇 |
1996年 | 15篇 |
1995年 | 14篇 |
1994年 | 22篇 |
1993年 | 18篇 |
1992年 | 6篇 |
1991年 | 4篇 |
1990年 | 7篇 |
1989年 | 26篇 |
1988年 | 23篇 |
1987年 | 27篇 |
1986年 | 18篇 |
1985年 | 21篇 |
1984年 | 23篇 |
1983年 | 14篇 |
1982年 | 13篇 |
1981年 | 19篇 |
1980年 | 16篇 |
1979年 | 3篇 |
1978年 | 11篇 |
1977年 | 8篇 |
1976年 | 7篇 |
1975年 | 5篇 |
1974年 | 4篇 |
1972年 | 3篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1969年 | 4篇 |
1968年 | 2篇 |
排序方式: 共有483条查询结果,搜索用时 171 毫秒
101.
102.
103.
为研究吸电子基团远离环氮的单环β-内酰胺类化合物对β-内酰胺酶的抑制作用,设计与合成了21个新的p-(3-酰氨基-4-取代苯基-2-吖丁啶酮基-1)苯乙酸和p-(3-酰氨基-4-取代苯基-2-吖丁啶酮基-1)苯乙酮类化合物,经元素分析、红外光谱、核磁共振氢谱和质谱证实。生物活性测定表明,其中15个具有游离羧基的水溶性化合物对试验的腊样芽胞杆菌和绿脓杆菌产生的β-内酰胺酶有抑制作用。 相似文献
104.
Hazlewood Glen S. Niaki Omid Zahedi Fitzcharles Mary-Ann 《Clinical rheumatology》2019,38(10):2655-2657
Clinical Rheumatology - 相似文献
105.
106.
107.
Autologous bone marrow transplantation is potentially curative in the treatment of acute leukemia if residual leukemic cells in the marrow can be eliminated prior to transplantation. We studied the purging effects of a synthetic alkyl-lysophospholipid (ALP) on marrow containing leukemic cells from a transplantable myelomonocytic leukemia (WEHI-3B) in BALB/c mice. Simulated remission bone marrow containing 2% leukemic cells treated in vitro with 20 and 100 micrograms/mL of ET-18- OCH3 (1-octadecyl-2-methyl-sn-glycerol-3-phosphocholine) significantly prolonged survival of lethally irradiated transplanted recipients. At a dose of 100 micrograms/mL, 88% of the mice survived for the duration of the experiment (approximately five months). Autopsies showed that 25% of these survivors had microscopic evidence of leukemia. Thus, in vitro treatment of marrow eliminated leukemic blasts and spared sufficient normal stem cells to allow hematologic reconstitution. The effect of ET- 18-OCH3 is not entirely selective for leukemic cells. A spleen colony assay showed that ALP has some cytotoxic effect on normal hematopoietic stem cells. 相似文献
108.
Goss GD; Wittwer MA; Bezwoda WR; Herman J; Rabson A; Seymour L; Derman DP; Mendelow B 《Blood》1985,66(5):1043-1046
Bone marrow transplantation for severe idiopathic aplastic anemia was undertaken in a patient, using his monozygotic twin brother as the donor. In spite of the use of syngeneic bone marrow, failure of engraftment occurred on two occasions. In vitro studies demonstrated that natural killer (NK) cells from the recipient markedly inhibited the growth of donor bone marrow granulocyte progenitor cells. On a third attempt, successful bone marrow engraftment was achieved following high-dose cyclophosphamide, which has previously been shown to be inhibitory to NK cells. We conclude that NK cell activity may play an important role in bone marrow failure as well as being responsible for at least some cases of aplastic anemia. 相似文献
109.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR 《Blood》1995,86(10):3987-3996
110.
Drobyski WR; Ash RC; Casper JT; McAuliffe T; Horowitz MM; Lawton C; Keever C; Baxter-Lowe LA; Camitta B; Garbrecht F 《Blood》1994,83(7):1980-1987
Between January 1988 and March 1993, 48 patients received T-cell- depleted marrow grafts from unrelated donors as treatment for chronic myelogenous leukemia (CML). The median age of the population was 31.7 years (range 5.4 to 53) with 17 of 48 patients greater than 40 years of age. Twenty-seven patients were transplanted in chronic phase, 17 in accelerated phase, and 4 in blast crisis. All patients received a standardized preparative regimen of cyclophosphamide, high-dose cytosine arabinoside, methylprednisolone, and total body irradiation. Marrow grafts were depleted of mature T cells with the alpha beta T- cell receptor antibody T10B9 as graft-versus-host disease (GVHD) prophylaxis. All patients also received posttransplant cyclosporine therapy. Twenty-eight of 48 patients were mismatched with their donors for one or more HLA-A, B, DR, or DQ loci by either serology or high- resolution oligonucleotide genotyping. Nine of 28 were mismatched at multiple HLA loci. Durable engraftment was achieved in 94% (45/48) of patients. The actuarial probability of developing grades II to IV and grades III to IV acute GVHD were 39.6% (95% confidence interval (CI) 26.9 to 53.0) and 8.3% (95% CI 6.1 to 10.9) for the entire cohort. There was no difference in the incidence of grades II to IV acute GVHD between patients receiving matched (36.8%) or mismatched (41.4%) marrow grafts (P = .77). The actuarial probability of relapse at 2 years was 8.8% (95% CI 2.1 to 21.6) for the entire cohort and 18% (95% CI 4 to 41) for patients transplanted in either the accelerated or blast crisis phase (advanced disease). One cytogenetic relapse has occurred among patients transplanted in the chronic phase. The probability of disease- free survival at 2 years was 52% (95% CI 24 to 70) for patients transplanted in chronic phase and 46% (95% CI 25 to 73) for patients transplanted with advanced disease. No difference in disease-free survival was observed between patients receiving matched (49%) or mismatched (51%) marrow grafts (P = .90). This study shows that patients receiving unrelated T-cell-depleted marrow grafts for CML can achieve durable engraftment with a low incidence of severe GVHD and apparent preservation of graft-versus-leukemia reactivity. These data also suggest that T-cell depletion may allow patients who might otherwise experience unacceptable toxicity from GVHD-related complications caused by older age or increased HLA disparity to benefit from unrelated marrow grafts. 相似文献